A “scoping” review of prostate brachytherapy and immune responses

  • Anthony T. Nguyen
    Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA

    Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
    Search for articles by this author
  • Chung-Tang Spencer Liu
    Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
    Search for articles by this author
  • Mitchell Kamrava
    Correspondence author. Department of Radiation Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048. Tel.: 310-423-1858; fax: 310-959-3332.
    Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA

    Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
    Search for articles by this author
Published:November 25, 2022DOI:



      Whether prostate brachytherapy (BT) results in opportunistic biological changes that can improve clinical outcomes is not well studied. We sought to investigate the impact of prostate BT on the immune system.

      Materials and Methods

      A scoping review was performed using PubMed/Scopus for papers published between 2011-2021. Search terms were “brachytherapy” AND “immune” AND “prostate”. A total of 81 records were identified and 6 were selected for further review.


      2 low-dose-rate BT papers (n=68) evaluated changes in the peripheral blood following I-125 monotherapy. Both showed significant increases in peripheral CD3+ and CD4+ T cells post-BT. One also demonstrated significant increases in Treg subsets up to 150 days post-BT. 4 high-dose-rate (HDR) studies (n=37) were identified, and all were done in combination with EBRT. The largest study (n=24) showed a single 10 Gy fraction of HDR converted 80% of “cold” tumors into an “intermediate” or “hot” state, based on a tumor inflammation signature when comparing a pre-BT biopsy to one prior to a second HDR fraction.


      Prostate BT can invoke an immune activating phenotype; however, changes in immunosuppressive cells are also seen. Additional data is needed to understand how to promote synergy between BT and the immune system.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33
        • Etzioni R.
        • Tsodikov A.
        • Mariotto A.
        • et al.
        Quantifying the role of PSA screening in the US prostate cancer mortality decline.
        Cancer Causes Control. 2008; 19: 175-181
        • Tsodikov A.
        • Gulati R.
        • A M Heijnsdijk Eveline
        • et al.
        Reconciling the effects of screening on Prostate Cancer mortality in the ERSPC and PLCO Trials.
        Ann Intern Med. 2017; 167: 449-455
        • Valle L.F.
        • Lehrer E.J.
        • Markovic D.
        • et al.
        A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER).
        Eur Urol. 2021; 80: 280-292
        • Spigel D.R.
        • Faivre-Finn C.
        • Gray J.E.
        • et al.
        Five-Year survival outcomes from the PACIFIC trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
        J Clin Oncol. 2022; 40: 1301-1311
        • Wolchok J.D.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Overall survival with combined nivolumab and ipilimumab in advanced melanoma.
        N Engl J Med. 2017; 377: 1345-1356
        • Bilusic M.
        • Einstein D.J.
        • Karzai F.H.
        • et al.
        The potential role for immunotherapy in biochemically recurrent prostate cancer.
        Urol Clin North Am. 2020; 47: 457-467
        • Ngwa W.
        • Irabor O.C.
        • Schoenfeld J.D.
        • et al.
        Using immunotherapy to boost the abscopal effect.
        Nat Rev Cancer. 2018; 18: 313-322
        • Nguyen A.T.
        • Shiao S.L.
        • McArthur H.L.
        Advances in combining radiation and immunotherapy in Breast Cancer.
        Clin Breast Cancer. 2021; 21: 143-152
        • Pointer K.B.
        • Pitroda S.P.
        • Weichselbaum R.R.
        Radiotherapy and immunotherapy: open questions and future strategies.
        Trends Cancer. 2022; 8: 9-20
        • Demaria S.
        • Guha C.
        • Schoenfeld J.
        • et al.
        Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?.
        J Immunother Cancer. 2021; 9e002038
        • Patel R.B.
        • Baniel C.C.
        • Sriramaneni R.N.
        • et al.
        Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.
        Brachytherapy. 2018; 17: 995-1003
        • Kubo M.
        • Satoh T.
        • Ishiyama H.
        • et al.
        Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.
        Oncol Rep. 2018; 39: 417-424
        • Du E.
        • Wang L.
        • Li C.Y.
        • et al.
        Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer.
        Onco Targets Ther. 2017; 10: 2561-2567
        • Williams S.G.
        • Aw Yeang H.X.
        • Mitchell C.
        • et al.
        Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.
        BMC Urol. 2020; 20: 171
        • Wang H.
        • Mendez L.C.
        • Morton G.
        • et al.
        Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: an exploratory study.
        Radiother Oncol. 2021; 155: 80-85
        • Keam S.P.
        • Halse H.
        • Nguyen T.
        • et al.
        High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
        J Immunother Cancer. 2020; 8e000792
        • Yuan Z.
        • Fernandez D.
        • Dhillon J.
        • et al.
        Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis.
        Prostate Cancer Prostatic Dis. 2021; 24: 140-149
        • Hamdy F.C.
        • Donovan J.L.
        • Lane J.A.
        • et al.
        10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer.
        N Engl J Med. 2016; 375: 1415-1424
        • Zumsteg Z.S.
        • Spratt D.E.
        • Pei I.
        • et al.
        A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
        Eur Urol. 2013; 64: 895-902
        • Keane F.K.
        • Chen M.H.
        • Zhang D.
        • et al.
        Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
        Cancer. 2015; 121: 2713-2719
        • Jones C.U.
        • Hunt D.
        • McGowan D.G.
        • et al.
        Radiotherapy and short-term androgen deprivation for localized prostate cancer.
        N Engl J Med. 2011; 365: 107-118
        • Zumsteg Z.S.
        • Spratt D.E.
        • Daskivich T.J.
        • et al.
        Effect of Androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable: a secondary analysis of the RTOG 9408 randomized clinical trial.
        JAMA Netw Open. 2020; 3e2015083
        • Kishan A.U.
        • Wang X.
        • Sun Y.
        • et al.
        High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP consortium.
        Eur Urol. 2022; 82: 106-114
        • Rajwa P.
        • Pradere B.
        • Gandaglia G.
        • et al.
        European association of urology young academic urologists prostate cancer working, intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis.
        Eur Urol. 2022; 82: 82-96
        • Lin L.
        • Kane N.
        • Kobayashi N.
        • et al.
        High-dose per fraction radiotherapy induces both antitumor immunity and immunosuppressive responses in Prostate Tumors.
        Clin Cancer Res. 2021; 27: 1505-1515
        • Eke I.
        • Aryankalayil M.J.
        • Bylicky M.A.
        • et al.
        Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.
        Cancer Immunol Immunother. 2022; 71: 839-850
        • Herberts C.
        • Annala M.
        • Sipola J.
        • et al.
        Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
        Nature. 2022; 608: 199-208
        • Kane N.
        • Romero T.
        • Diaz-Perez S.
        • et al.
        Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT.
        Prostate Cancer Prostatic Dis. 2022; (Online ahead of print)
        • Hammer L.
        • Jiang R.
        • Hearn J.
        • et al.
        A Phase I Trial of neoadjuvant stereotactic body radiotherapy prior to radical prostatectomy for locally advanced prostate cancer.
        Int J Radiat Oncol Biol Phys. 2022; (; S0360-3016(22)00736-2. Online ahead of print)
        • Keam S.P.
        • Caramia F.
        • Gamell C.
        • et al.
        The transcriptional landscape of radiation-treated human prostate cancer: analysis of a prospective tissue cohort.
        Int J Radiat Oncol Biol Phys. 2018; 100: 188-198
        • Postow M.A.
        • Callahan M.K.
        • Barker C.A.
        • et al.
        Immunologic correlates of the abscopal effect in a patient with melanoma.
        N Engl J Med. 2012; 366: 925-931
        • McBride S.
        • Sherman E.
        • Tsai C.J.
        • et al.
        Randomized Phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma.
        J Clin Oncol. 2021; 39: 30-37
        • Lee N.Y.
        • Ferris R.L.
        • Psyrri A.
        • et al.
        Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
        Lancet Oncol. 2021; 22: 450-462
        • Machiels J.P.
        • Tao Y.
        • Burtness B.
        • et al.
        Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
        Future Oncol. 2020; 16: 1235-1243
        • Mayadev J.
        • Nunes A.T.
        • Li M.
        • et al.
        CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
        Int J Gynecol Cancer. 2020; 30: 1065-1070
        • Marciscano A.E.
        • Ghasemzadeh A.
        • Nirschl T.R.
        • et al.
        Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy.
        Clin Cancer Res. 2018; 24: 5058-5071